Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUYOC8)

Drug Name

AP12009 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]

Therapeutic Class

Antisense

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transforming growth factor beta 2 (TGFB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lerdelimumab	DME91CG	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transforming growth factor beta 2 (TGFB2)	TTY9TWO	TGFB2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00761280) Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma. U.S. National Institutes of Health.
2	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
3	A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007 Oct;114(10):1822-30.